Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -3.10 is 125% below its 3-year average of -1.38, near the low end of its 3-year range (-3.10–-0.73).
64.46% below its 12-month average of -1.89.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.82.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 10 comparable quarters.
EARNINGS PER SHARE (EPS)
-3.10
EARNINGS PER SHARE (EPS) AVG TTM
-1.89
EARNINGS PER SHARE (EPS) AVG 3Y
-1.38
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-64.46%
CURRENT VS 3Y AVG
-125.45%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Bicara Therapeutics Inc. Common Stock
Market Cap
$1.09B
Earnings Per Share (EPS)
-3.10
TTM Avg
-1.89
3Y Avg
-1.38
5Y Avg
N/A
Market Cap
$1.09B
Earnings Per Share (EPS)
1.79
TTM Avg
1.65
3Y Avg
1.42
5Y Avg
1.09
Market Cap
$1.11B
Earnings Per Share (EPS)
1.69
TTM Avg
2.70
3Y Avg
2.53
5Y Avg
1.91
Market Cap
$1.12B
Earnings Per Share (EPS)
-0.99
TTM Avg
-0.32
3Y Avg
-0.47
5Y Avg
-0.45
Market Cap
$1.05B
Earnings Per Share (EPS)
-0.66
TTM Avg
-0.08
3Y Avg
-1.22
5Y Avg
-1.11
Market Cap
$1.05B
Earnings Per Share (EPS)
-0.99
TTM Avg
-3.50
3Y Avg
-23.24
5Y Avg
-16.84
Market Cap
$1.13B
Earnings Per Share (EPS)
N/A
TTM Avg
-3.20
3Y Avg
-3.20
5Y Avg
-3.20
Market Cap
$1.14B
Earnings Per Share (EPS)
N/A
TTM Avg
-2.04
3Y Avg
-2.04
5Y Avg
-2.04
Market Cap
$1.13B
Earnings Per Share (EPS)
-124.78
TTM Avg
-85.76
3Y Avg
-67.06
5Y Avg
-58.99
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $1.09B | -3.10 | -1.89 | -1.38 | N/A |
| IRadimed Corporation (IRMD)vs › | $1.09B | 1.79 | 1.65 | 1.42 | 1.09 |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.11B | 1.69 | 2.70 | 2.53 | 1.91 |
| Harrow Health, Inc. (HROW)vs › | $1.12B | -0.99 | -0.32 | -0.47 | -0.45 |
| Castle Biosciences, Inc. (CSTL)vs › | $1.05B | -0.66 | -0.08 | -1.22 | -1.11 |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | -0.99 | -3.50 | -23.24 | -16.84 |
| Kardigan, Inc. (KARD)vs › | $1.13B | N/A | -3.20 | -3.20 | -3.20 |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.14B | N/A | -2.04 | -2.04 | -2.04 |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.13B | -124.78 | -85.76 | -67.06 | -58.99 |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 0.04 | 0.06 | 0.01 | -0.18 |
Trailing EPS (TTM)
$-3.10
Forward EPS (Est.)
$-3.42
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.52 |
| 2024-12-31 | -1.25 |
| 2023-12-31 | -1.00 |
| 2022-12-31 | -0.73 |
